Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96QU6
UPID:
1A1L1_HUMAN
Alternative names:
-
Alternative UPACC:
Q96QU6; B4E219; Q8WUL4; Q96LX5
Background:
The 1-aminocyclopropane-1-carboxylate synthase-like protein 1, identified by the accession number Q96QU6, showcases a unique enzymatic activity. Unlike its name suggests, it does not facilitate the synthesis of 1-aminocyclopropane-1-carboxylate, a key precursor in ethylene biosynthesis. Instead, it specializes in the deamination of L-vinylglycine, a process with implications in various metabolic pathways.
Therapeutic significance:
Understanding the role of 1-aminocyclopropane-1-carboxylate synthase-like protein 1 could open doors to potential therapeutic strategies. Its unique enzymatic function suggests a specialized role in metabolic processes, which, when elucidated, may offer novel insights into metabolic disorder treatments.